This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: May 26, 2006
Last updated: December 14, 2006
Last verified: December 2006
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.

Condition Intervention Phase
Obesity Drug: Peptide YY3-36 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Food intake

Secondary Outcome Measures:
  • Plasma biomarkers, safety, toleration

Estimated Enrollment: 31
Study Start Date: July 2006
Estimated Study Completion Date: December 2006

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI 27-35 kg/m2

Exclusion Criteria:

  • Women of childbearing potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00331175

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information: Identifier: NCT00331175     History of Changes
Other Study ID Numbers: A9001292
Study First Received: May 26, 2006
Last Updated: December 14, 2006

Additional relevant MeSH terms:
Body Weight
Signs and Symptoms processed this record on August 18, 2017